Industries > Pharma > Hepatitis C Therapies Market 2017-2027

Hepatitis C Therapies Market 2017-2027

Revenue Forecasts for Hepatitis C Therapeutics, Direct-Acting Antivirals, Ribavirin, Protease Inhibitors, Polymerase Inhibitors, Interferons & R&D

PUBLISHED: 24 October 2017
PAGES: 180
PRODUCT CODE: PHA0251

Clear
WOOCS 2.2.1
SKU: PHA0251 Categories: , , Tag:

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 180-page report you will receive 67 tables and 50 figures– all unavailable elsewhere.

The 180-page report provides clear detailed insight into the Hepatits C Therapies market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand new report today you stay better informed and ready to act.

The revenue of the Hepatitis C market in 2016 is estimated at $19bn and is expected to grow at a CAGR of 1.7% in the first half of the forecast period. Oral antivirals accounted for the largest share of the market in 2016, this segment generated $18.7bn.

Read on to discover how this definitive report can transform your own research and save you time.
The new market assessment benefits research, analysis and planning in seven main ways:
• World HCV market revenue to 2027 – discover that industry’s overall sales potential
• Two product classes’ revenues to 2027 – investigate categories at world level, finding the most lucrative and promising therapy classes
• Eight leading drugs’ revenues to 2027 – find sales predictions for top and emerging products, seeing how agents compete and succeed
• 11 national markets in the Americas, Europe and Asia covered, with forecasts to 2027 – discover the best countries for trade expansion
• Activities of established, rising and emerging companies – hear about firms’ products, capabilities, advances, collaborations and outlooks
• R&D for antiviral medicines – investigate progress in that industry, exploring technological, clinical and commercial opportunities
• Analysis of what stimulates and restrains that industry and market – assess challenges, strengths, competition and opportunities, helping you succeed.

There you explore business intelligence with research, opinions and predictions found only in that work.

Trying our investigation now lets you discover trends, opportunities and prospects
For treating hepatitis C virus, our report shows you data, trends, opportunities and multilevel sales forecasts. So, avoid missing out. Instead please get that new analysis here now.

Report highlights
• 192 pages, 67 tables and 50 figures

• Hepatitis C Market Therapies Market Forecast from 2017 to 2027
• This report also breaks down the revenue forecast for the main submarkets:
• Oral Antivirals
• Interferons

• Analysis of the Oral Antivirals drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Harvoni
• Sovaldi
• Epclusa
• Daklinza

• Analysis of the Interferons drugs market. Revenue forecasts to 2027 are provided for the following drugs:
• Pegasys
• PegIntron

• Analysis of key players in Hepatitis C Therapeutics
• Gilead Sciences
• Merck and Co.
• Roche
• Bristol Myers Squibb
• Janssen
• Achillion Pharmaceuticals

Healthcare Packaging Market Report 2017-2027

• Regional Hepatitis C market forecasts from 2017-2027
• US forecast 2017-2027,
• China forecast 2017-2027
• Japan forecast 2017-2027
• India forecast 2017-2027
• Germany forecast 2017-2027
• UK forecast 2017-2027
• France forecast 2017-2027
• Brazil Forecast 2017-2027
• Russia Forecast 2017-2027

• Key questions answered
• What does the future hold for the Hepatitis C Therapies industry?
• Where should you target your business strategy?
• What technologies give the most promising candidates for new drugs?
• Which disruptive technologies should you invest in?
• Which companies should you form strategic alliances with?
• Which company is likely to success and why?
• What business models should you adopt?
• What industry trends should you be aware of?
• Which is the company with the highest expected revenue from 2017 to 2027?
• Where lie the best geographical opportunities for selling those antivirals?
• Why will the HCV drug market expand, and what limits its sales growth?
• How will companies overcome challenges in serving regulators, patients and payers?

• Target audience
• Leading Hepatitis C companies
• Suppliers
• Contractors
• Technologists
• R&D staff
• Consultants
• Analysts
• CEO’s
• CIO’s
• COO’s
• Business development managers
• Investors
• Governments
• Agencies
• Industry organisations
• Banks

With our study you see how that market can develop and perform, benefiting your reputation for insight and authority.

Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6

Download sample pages

Complete the form below to download your free sample pages for Hepatitis C Therapies Market 2017-2027


Download sample pages

Complete the form below to download your free sample pages for Hepatitis C Therapies Market 2017-2027


Latest Pharma news

Visiongain Publishes Direct-to-Patient Market Report 2021-2031

Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.

21 July 2021

READ

Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031

Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.

20 July 2021

READ

Visiongain Publishes Pharma Contract Sales Market Report 2021-2031

Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.

14 July 2021

READ

Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2021-2031

Digital innovation in clinical trials and renewed focus on home production will ensure a high growth market for supply chain optimisation.

12 July 2021

READ

Categories